Management | CALVERT Research

Management

Calvert Research is composed of a group of senior pharmaceutical and biotechnology executives who are experienced in all facets of our innovative business model.


R.C. McLauchlan
Chairman 

Russ McLauchlan founded Calvert Holdings in March 1996 following twenty-six years in the pharmaceutical and biotechnology industry. He has led the company through its acquisition and internal development of key units resulting in an operation capable of providing significant drug testing and development, capital investment, management, and marketing services for emerging biodiscovery and other business organizations.

Prior to founding Calvert, McLauchlan served as president with an early stage pharmaceutical company and a biotechnology company and as an executive with a multinational pharmaceutical/chemical company. He also served as a board member of national and state biotechnology trade associations.

 


Michael A. Recny, PhD
President & Chief Executive Officer

Dr. Recny is a veteran drug developer with more than 25 years experience in the biotechnology industry. During his career, he has contributed to the research, development and/or commercialization of three FDA approved drugs that have collectively achieved billions in worldwide sales, and to four other drug candidates that have entered human clinical trials.  Dr. Recny is responsible for building and managing the portfolio of corporate risk-sharing partnerships for Calvert Research and structures all partnership transactions for the company.

Prior to joining Calvert in 2007, Dr. Recny spent 12 years with Trimeris, Inc. as Vice President of Corporate Development where he led Trimeris’ 1997 internal IPO team and made significant contributions to the development and approval of FUZEON®, Trimeris’ first-in-class HIV antiviral.  Together with Trimeris’ General Counsel, Dr. Recny structured one of the first 50/50 co-development and profit share partnerships in the industry with Hoffmann-La Roche, Ltd. (1999) to advance FUZEON from Phase II to worldwide approval and commercial launch in 2003. Prior to Trimeris, Dr. Recny was Director of Protein Biochemistry at Procept, Inc. where he helped structure three collaborative R&D agreements with international pharmaceutical companies over a five year period.  Earlier in his career, Dr Recny was a Staff Scientist and Laboratory Head at Genetics Institute, Inc. (now a division of Pfizer, Inc.), where his laboratory was the first to publish the correct protein structure and biological activity of natural and recombinant human erythropoietin.

Dr. Recny attended the University of Rochester as a Joseph C. Wilson Scholar and earned a bachelor’s degree in Biochemistry.  He received his Ph.D. in Biochemistry from the University of Illinois, Urbana-Champaign.  He conducted postdoctoral work through joint academic appointments at the Dana Farber Cancer Institute (Boston, MA) and Harvard Medical School and is a co-author of numerous peer-reviewed publications in the scientific literature.  He has also served as a Board Member and business advisor to numerous early stage technology companies.